BBOT vs CB · $610.4M cap vs P/E 14, rev $59.40B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Chubb Ltd (CB) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
BBOT does not have a complete income-statement cache yet.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
BBOT currently screens at market cap $610.4M. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Not investment advice. Open the BBOT and CB stock pages for the full models.
Not investment advice.